Cost Effectiveness of Insulin Glargine/Lixisenatide for Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin in South Korea

• 발행기관: 대한약학회
• 저자명: Hae-Young Park Sena An Susan Park Dong-Ha Kim Hye Ok Kim Jeong-Mi Kwon Jin-Won Kwon
• 간행물 정보: 『약학회지』제63권 제1호(2019년), 1~14쪽, 전체 14쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2019.01.30

영문 초록

This study aimed to assess the cost-effectiveness of insulin glargine/lixisenatide (iGlarLixi) in comparison with premixed insulin for patients with basal insulin-uncontrolled type 2 diabetes in South Korea. The CORE Diabetes Model, a Markov model, was used with the following settings: a 30 year horizon, a payer perspective, and a 3% discount rate. Each treatment was assumed to be administered for the first 3 years, and then switched to rescue regimen. The baseline HbA1c and body mass index (BMI) were 8.6 ± 1.3%, and 24.4 ± 3.3 kg/m2, respectively. Indirect treatment comparisons showed that iGlarLixi resulted in significantly greater reduction from baselines for HbA1c and BMI compared with premixed insulin; −0.50% (95% confidence interval (CI): −0.68, −0.32) for HbA1c and −0.80 kg/m2 (95% CI: −1.29, −0.31) for BMI. In the base analysis, iGlarLixi was found to be dominant (more effective and less costly) over premixed insulin with 0.079 additional quality-adjusted life-years and lowered cost by approximately 230 USD, and the incremental costutility ratios from sensitivity analyses also remained dominant or below 10,000 USD. This study demonstrated that iGlarLixi was cost effective for treating patients with type 2 diabetes with poor glucose control on basal insulin in comparison with premixed insulin in South Korea.

목차

Introduction

Experimental Methods

Experimental Results

Discussion

Acknowledgment

Conflict of Interest

References

키워드

Cost-utility analysis insulin glargine glucagon-like peptide-1 receptor diabetes mellitus